Literature DB >> 29141161

Cognitive Function in a Randomized Trial of Evolocumab.

Robert P Giugliano1,2, Marc S Sabatine1, Brian R Ott3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29141161     DOI： 10.1056/NEJMc1712102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

Review 2.  High-intensity statin therapy yields better outcomes in acute coronary syndrome patients: a meta-analysis involving 26,497 patients.

Authors:  Shiyong Yu; Jun Jin; Zhongxiu Chen; Xiaolu Luo
Journal:  Lipids Health Dis       Date:  2020-08-23       Impact factor: 3.876

3.  Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer's Disease.

Authors:  Maria Pia Adorni; Massimiliano Ruscica; Nicola Ferri; Franco Bernini; Francesca Zimetti
Journal:  Front Aging Neurosci       Date:  2019-05-22       Impact factor: 5.750

4.  Assessment of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials.

Authors:  Alison Offer; Matthew Arnold; Robert Clarke; Derrick Bennett; Louise Bowman; Richard Bulbulia; Richard Haynes; Jing Li; Jemma C Hopewell; Martin Landray; Jane Armitage; Rory Collins; Sarah Parish
Journal:  JAMA Netw Open       Date:  2019-03-01

5.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.

Authors:  Cynthia Picard; Alexandre Poirier; Stéphanie Bélanger; Anne Labonté; Daniel Auld; Judes Poirier
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

Review 6.  Current Options and Future Perspectives in the Treatment of Dyslipidemia.

Authors:  Saverio Muscoli; Mihaela Ifrim; Massimo Russo; Francesco Candido; Angela Sanseviero; Marialucia Milite; Marco Di Luozzo; Massimo Marchei; Giuseppe Massimo Sangiorgi
Journal:  J Clin Med       Date:  2022-08-12       Impact factor: 4.964

7.  Depression and cardiovascular risk-association among Beck Depression Inventory, PCSK9 levels and insulin resistance.

Authors:  C Macchi; C Favero; A Ceresa; L Vigna; D M Conti; A C Pesatori; G Racagni; A Corsini; N Ferri; C R Sirtori; M Buoli; V Bollati; M Ruscica
Journal:  Cardiovasc Diabetol       Date:  2020-11-03       Impact factor: 8.949
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.